[go: up one dir, main page]

WO2000052045A3 - Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof - Google Patents

Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof Download PDF

Info

Publication number
WO2000052045A3
WO2000052045A3 PCT/EP2000/001458 EP0001458W WO0052045A3 WO 2000052045 A3 WO2000052045 A3 WO 2000052045A3 EP 0001458 W EP0001458 W EP 0001458W WO 0052045 A3 WO0052045 A3 WO 0052045A3
Authority
WO
WIPO (PCT)
Prior art keywords
mage
mhc
class
immunogenic peptides
peptides presented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2000/001458
Other languages
French (fr)
Other versions
WO2000052045A2 (en
Inventor
Maria Pia Protti
Paolo Dellabona
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ospedale San Raffaele SRL
Original Assignee
Ospedale San Raffaele SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ospedale San Raffaele SRL filed Critical Ospedale San Raffaele SRL
Priority to CA002364002A priority Critical patent/CA2364002A1/en
Priority to JP2000602269A priority patent/JP2002538166A/en
Priority to EP00907601A priority patent/EP1161443A2/en
Priority to AU29134/00A priority patent/AU2913400A/en
Publication of WO2000052045A2 publication Critical patent/WO2000052045A2/en
Publication of WO2000052045A3 publication Critical patent/WO2000052045A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Peptides derived from the protein MAGE-3, pharmaceutical compositions containing them and the use thereof for inducing an immune response against tumors.
PCT/EP2000/001458 1999-02-26 2000-02-23 Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof Ceased WO2000052045A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002364002A CA2364002A1 (en) 1999-02-26 2000-02-23 Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof
JP2000602269A JP2002538166A (en) 1999-02-26 2000-02-23 MAGE-3 derived immunogenic peptides presented by MHC class II and uses thereof
EP00907601A EP1161443A2 (en) 1999-02-26 2000-02-23 Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof
AU29134/00A AU2913400A (en) 1999-02-26 2000-02-23 Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999MI000396A IT1309584B1 (en) 1999-02-26 1999-02-26 IMMUNOGENIC PEPTIDES DERIVED FROM MAGE-3 PRESENTED BY MHC OF CLASS II AND THEIR USE.
ITMI99A000396 1999-02-26

Publications (2)

Publication Number Publication Date
WO2000052045A2 WO2000052045A2 (en) 2000-09-08
WO2000052045A3 true WO2000052045A3 (en) 2001-01-04

Family

ID=11382063

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/001458 Ceased WO2000052045A2 (en) 1999-02-26 2000-02-23 Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof

Country Status (6)

Country Link
EP (1) EP1161443A2 (en)
JP (1) JP2002538166A (en)
AU (1) AU2913400A (en)
CA (1) CA2364002A1 (en)
IT (1) IT1309584B1 (en)
WO (1) WO2000052045A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001253029A1 (en) * 2000-03-30 2001-10-15 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services T-cell epitope of mage-12 and related nucleic acids, vectors, cells, compositions and methods of inducing an immune response to cancer
AU2002322009A1 (en) 2001-05-18 2002-12-03 Mayo Foundation For Medical Education And Research Chimeric antigen-specific t cell-activating polypeptides
US20060222656A1 (en) 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
US7049413B2 (en) * 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
FR2837837B1 (en) * 2002-03-28 2006-09-29 Roussy Inst Gustave PEPTIDE EPITOPES COMMON TO ANTIGENS OF THE SAME MULTIGENIC FAMILY
EP1715343B1 (en) * 2005-04-20 2009-12-09 F. Hoffmann-La Roche Ag Method for the identification of epitopes related to immunogenicity in biopharmaceuticals
WO2008053573A1 (en) * 2006-10-30 2008-05-08 National University Corporation Hokkaido University Remedy for malignant neoplasm
TWI546381B (en) * 2014-05-30 2016-08-21 中央研究院 Aptamer targeting mage-a3 peptide and uses thereof
GB201804468D0 (en) 2018-03-21 2018-05-02 Valo Therapeutics Oy PeptiCRAd Cancer Therapy

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020127A1 (en) * 1993-03-05 1994-09-15 Cytel Corporation Hla-a2.1 binding peptides and their uses
WO1995019783A1 (en) * 1994-01-25 1995-07-27 Cytel Corporation Induction of anti-tumor cytotoxic t lymphocytes in humans using synthetic peptide epitopes
WO1998033888A1 (en) * 1997-01-31 1998-08-06 Epimmune, Inc. Peptides and peptide-loaded antigen presenting cells for the activation of ctl
WO1999003972A1 (en) * 1997-07-15 1999-01-28 Takara Shuzo Co., Ltd. Cytotoxic t lymphocytes
WO1999014326A1 (en) * 1997-09-12 1999-03-25 Ludwig Institute For Cancer Research Mage-3 peptides presented by hla class ii molecules
WO1999045954A1 (en) * 1998-03-13 1999-09-16 Epimmune, Inc. Hla-binding peptides and their uses

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994020127A1 (en) * 1993-03-05 1994-09-15 Cytel Corporation Hla-a2.1 binding peptides and their uses
WO1995019783A1 (en) * 1994-01-25 1995-07-27 Cytel Corporation Induction of anti-tumor cytotoxic t lymphocytes in humans using synthetic peptide epitopes
WO1998033888A1 (en) * 1997-01-31 1998-08-06 Epimmune, Inc. Peptides and peptide-loaded antigen presenting cells for the activation of ctl
WO1999003972A1 (en) * 1997-07-15 1999-01-28 Takara Shuzo Co., Ltd. Cytotoxic t lymphocytes
WO1999014326A1 (en) * 1997-09-12 1999-03-25 Ludwig Institute For Cancer Research Mage-3 peptides presented by hla class ii molecules
WO1999045954A1 (en) * 1998-03-13 1999-09-16 Epimmune, Inc. Hla-binding peptides and their uses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHAUX P ET AL: "IDENTIFICATION OF MAGE-3 EPITOPES PRESENTED BY HLA-DR MOLECULES TO CD4+ T LYMPHOCYTES", JOURNAL OF EXPERIMENTAL MEDICINE,JP,TOKYO1, vol. 189, no. 5, 1 March 1999 (1999-03-01), pages 767 - 777, XP000857617, ISSN: 0022-1007 *

Also Published As

Publication number Publication date
IT1309584B1 (en) 2002-01-24
ITMI990396A1 (en) 2000-08-26
JP2002538166A (en) 2002-11-12
WO2000052045A2 (en) 2000-09-08
AU2913400A (en) 2000-09-21
CA2364002A1 (en) 2000-09-08
EP1161443A2 (en) 2001-12-12

Similar Documents

Publication Publication Date Title
WO2002080965A3 (en) Vaccine composition
EP1203817A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
WO1999042076A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
WO1998016646A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
WO2004075829A3 (en) Adjuvanted influenza vaccine
WO2000062800A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
MY125202A (en) Vaccine
NO20001768L (en) Virus encapsulation vaccine, method of preparation and use thereof
IS4518A (en) New vaccine formulation
EP2172551A3 (en) Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
WO2001081609A3 (en) Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
NO992102D0 (en) Peptide composition, as well as pharmaceutical composition and cancer vaccine including the peptide composition
WO2005007673A3 (en) Immunogenic peptides
WO2002087494A3 (en) Novel vaccine
EP2502998A3 (en) Recombinant toxin A/ToxinB vaccine against clostridium difficile
WO2000052045A3 (en) Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof
HK1046925A1 (en) Mage-a12 antigenic peptides and uses thereof
WO2003093298A3 (en) Immunogenic peptides
WO2002040518A8 (en) Periplasmic domain of an enterobacterium omp protein and its use as carrier or adjuvant
WO2000055194A3 (en) Tuberculosis antigens and methods of use therefor
WO2005037236A3 (en) Novel heat shock protein 20-related polypeptides and uses therefor
WO2004092207A3 (en) Respiratory syncytial virus (rsv) peptides
AU2002352011A1 (en) Immunogenic alk (anaplastic lymphoma kinase) peptides
WO2002030458A8 (en) Yersinia adhesion protein as vaccine adjuvant

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000907601

Country of ref document: EP

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 602269

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref document number: 2364002

Country of ref document: CA

Ref country code: CA

Ref document number: 2364002

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09914239

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000907601

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000907601

Country of ref document: EP